Skip header and navigation

1 records – page 1 of 1.

A DTaP-IPV//PRP~T vaccine (Pentaxim™): a review of 16 years' clinical experience.

https://arctichealth.org/en/permalink/ahliterature101502
Source
Expert Rev Vaccines. 2011 Jul;10(7):981-1005
Publication Type
Article
Date
Jul-2011
Author
Stanley A Plotkin
Johannes Liese
Shabir A Madhi
Esteban Ortiz
Author Affiliation
Vaxconsult, PA, USA.
Source
Expert Rev Vaccines. 2011 Jul;10(7):981-1005
Date
Jul-2011
Language
English
Publication Type
Article
Abstract
Owing to their low reactogenicity, confirmed efficacy and availability in combination vaccines, acellular pertussis (aP)-inactivated poliovirus (IPV) combined vaccines are now included in various national immunization programs worldwide. We provide an overview of 16 years of clinical experience with a diphtheria (D), tetanus (T), aP, IPV and Haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (PRP~T) combined vaccine (DTaP-IPV//PRP~T - Pentaxim?, Sanofi Pasteur, France). Good immunogenicity has been demonstrated after primary vaccination with Pentaxim, regardless of the population ethnicity and primary vaccination schedule. A booster vaccination in the second year of life also resulted in a high immune response for each antigen. Furthermore, 10 years of national surveillance in Sweden has demonstrated the effectiveness of Pentaxim in controlling pertussis. As is the case for other aP-containing combined vaccines, Pentaxim is well tolerated, with the safety profile being better than for whole-cell pertussis-containing combination vaccines for primary and booster vaccinations.
PubMed ID
21749196 View in PubMed
Less detail